Facts
as of Nov 17, 2026
Our mission is to innovate therapies that have the potential to shift the treatment of hematological,pulmonary and cardiovascular disorders.
It is hiring: 8 open roles, 3 of them posted in the last 30 days.
- Legal name
- Keros Therapeutics, Inc.
- Headquarters
- Lexington, United States
- Founded
- 2015
- Employees
- 51-200estimated range
- Listing
- NASDAQ: KROS
- Open roles
- 8Alion job postings
- Register numbers
- NAME keros therapeutics inc
- Website
- kerostx.com
As of Nov 17, 2026, Alion lists 8 open roles at Keros Therapeutics. Keros Therapeutics is headquartered in Lexington, United States. It was founded in 2015.
Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake
What the registers and the postings say about this employer.
Legal entity active
Keros Therapeutics, Inc.
Not checked
Sanctions lists
OFAC SDN, EU consolidated
No match
Phishing reports
OpenPhish, Phishing.Database
None
Layoff notices
US WARN notices on file
None
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices
Hiring steadily, with new roles every week.
Science & Research is the largest family, 27 of open roles.
3Posted in 30 days38% of open roles are fresh
13%Remote roles1 of 8
1Hiring offices
Can they hire you from United States?by your location
Likely
21 open roles are in your country: you apply locally, no move needed.
United States21On site
Remote, from elsewhere1Rare
No posting offers visa sponsorship. Remote roles: 1.
Time to fillmedian days to close a role
Keros Therapeutics55 days
Market, same roles29 days
Alion signals0-100
Demand20
Pay49
Your chance44
How badly they need people, whether they pay, how realistic getting in is.
Open roles over time−100%
Sep 21This week
Open roles a week: 16 then, 0 now
Where the openings areshare of open roles · trend
Science & Research27▼
Biotech27▲
Industrial Engineering14▼
Support9▼
Finance9▼
DevOps5▲
Degree asked
Doctoral Degree (PhD) 43%Master's Degree 29%Associate's Degree 14%Bachelor's Degree 14%
7 postings state a degree.
Benefits named in postingsshare of open roles
Contract type
Contract 2
Visa sponsorship: none statedRelocation: none stated
Source: the company's careers site, read by Alion several times a day; market medians from all open roles of the same family
Pay
What its postings pay, by level.
$267kMedian
$250k – $277kTypical rangeUSD a year
$303kHighest paying roleSenior Director, Toxicology
Pay by levelmiddle half of stated pay, median marked
Head+4$257k$250k – $277k
$0$88k$175k$263k$350k
Source: the pay stated in the company's postings, normalised to USD a year
Named in the work visa registers of United States.
0H-1B filings in 12 months
8Open roles in United States
In the register as Keros Therapeutics, Lexington, MA
Other sponsors in the same field
US Department of Labor · latest filing May 8, 2025
Footprint
Hiring in 1 city in 1 country.
1Cities
1Countries
LexingtonBusiest site
Source: office addresses in postings and company registers
Technologies named in job postings at Keros Therapeutics over the last 12 months, by layer, with the share of postings for each.
23Technologies in use
17Postings analysed
57/100Stack modernity
Sign in to see how your skills match this stackSign In
Source: the technologies named in the company's postings and on its site
Milestones
Each milestone is dated by its source: registers, filings, the press
Newsroom
Sep 292026
News · YahooFinance
Keros Therapeutics (KROS) said Tuesday it expects to receive a $20 million development milestone pay
Sep 292026
News · YahooFinance
LEXINGTON, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (
Sep 282026
News · YahooFinance
Initial data expected in the first half of 2027LEXINGTON, Mass., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (
Sep 282026
News · marketscreener.com
Sep 92026
Press release · The Globe and Mail
Detailed price information for Keros Therapeutics Inc (KROS-Q) from The Globe and Mail including charting and trades.
Sources: the outlets named on each headline, each story once